Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis, Precision Bio Differ on EPO Decision Regarding Gene-Engineering Patent

NEW YORK (GenomeWeb News) – French genome engineering company Cellectis said yesterday that that the European Patent Office has upheld one of its patents that has been the subject of ongoing litigation with US biotech firm Precision BioSciences.

However, in a statement released this morning, Precision BioSciences said that the EPO had "severely restricted" Cellectis' claims under the patent.

The patent, EP 1485475, relates to engineering methods for meganucleases, and is owned by Cellectis. Precision BioSciences, based in Research Triangle Park, NC, requested a re-examination of the patent after Cellectis sued Precision for allegedly infringing it.

The engineering methods described in the patent are based on the genetic fusion of meganuclease modules to obtain hybrid meganucleases, Cellectis said.

"This decision makes us even more determined in our constant fight to defend our intellectual property rights," Cellectis CEO André Choulika said in a statement.

While Cellectis claimed the EPO's decision went in its favor, Precision Bio said that the office revoked previously granted claims in the patent. It said that claims to single-chain meganucleases, including those derived from I-Crel, "were revoked in their entirety," while claims to hybrid meganucleases "were cancelled or severely restricted."

"Oddly, Cellectis issued a press release claiming that the EPO 'upheld' their patent despite the fact that they lost all of their claims to single-chain meganucleases," Precision BioSciences CEO Matthew Kane, said in a statement. "We hope all of their patents are similarly 'upheld.'"

The US Patent and Trademark Office is currently re-examining a pair of related patents owned by the Institut Pasteur and Universite Pierre et Marie Curie and licensed exclusively to Cellectis. Precision also requested a re-examination of these patents, US Nos. 6,610,545 and 7,309,605, after Cellectis sued Precision for allegedly infringing them.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.